Skip to content

Journal of Affective Disorders

ISSN 0165-0327

30 papers in the library · 1,925 citations · publishing 2014-2026

Papers

Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression

Journal of Affective Disorders February 12, 2026 Erica Kaczmarek, Nelson Rodriguez, Noah Chisamore et al.

Anhedonia, a core symptom of depression that often resists standard treatments, may be reduced by psilocybin-assisted psychotherapy (PAP). In a secondary analysis of a randomized, waitlist-controlled trial, 30 adults with treatment-resistant depression (major depressive disorder or bipolar II disorder) received one 25 mg dose of oral psilocybin plus psychotherapy. Anhedonia severity, measured by the Snaith-Hamilton Pleasure Scale, decreased significantly at the 2-week primary endpoint, with clinically meaningful improvements persisting at 3 and 6 months. The analysis adjusted for sex and age. These preliminary results suggest PAP could be a promising intervention for anhedonia in treatment-resistant depression, though larger placebo-controlled trials are needed to confirm the findings and clarify underlying mechanisms.

DOI: 10.1016/j.jad.2026.121385 Psilocybin Major depressive disorder Anhedonia Depression economics +11

Insights into psilocybin use among people with bipolar disorder: A thematic analysis of Reddit posts

Journal of Affective Disorders January 20, 2026 Laura Mills, Susan L. Rossell, Sean Carruthers

Psilocybin use among people with bipolar disorder is associated with both benefits and risks. Analysis of 354 Reddit posts and comments revealed four themes: mania, depression, mixed experiences, and broader perspectives. Some users reported reduced depression symptoms and shifts in perspective, but others described increased or new mania, psychosis, and worsened depression. The findings suggest that while psilocybin may help some individuals with bipolar disorder, it also carries potential for adverse mental health effects.

DOI: 10.1016/j.jad.2026.121220 Psilocybin Thematic analysis Mania Psychosis +11

Insights from the psychedelic experience integration session: Verbatims differentiate 3-month abstinence in alcohol use disorder with depressive symptoms

Journal of Affective Disorders January 19, 2026 Maria Garcia Garcia, Dahbia Belahda, Carine Graux et al.

In psilocybin-assisted psychotherapy, participants who responded to treatment described their experience as an inner dialogue and used adaptive coping strategies, while non-responders focused on sensory and affective details and relied on suppressive coping. The presence of inner dialogue may represent a unique therapeutic mechanism, underscoring the value of preparation and integration in such therapy.

DOI: 10.1016/j.jad.2026.121215 Alcohol use disorder Major depressive disorder Abstinence Depressive symptoms +6

A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions.

Journal of Affective Disorders December 29, 2020 Nelson B Rodrigues, R. Mcintyre, Orly Lipsitz et al.

A 6-item short form of the Clinician-Administered Dissociative States Scale (CADSS-6) strongly correlates with the full 23-item version in patients with treatment-resistant depression receiving IV ketamine. Using retrospective data from 260 patients split into two groups, the CADSS-6 was derived from items most sensitive to ketamine-induced dissociation. Correlations between the short and full scale ranged from 0.91 to 0.95 across four infusions. The CADSS-6 offers a brief clinical assessment for dissociation, though it remains unvalidated in this population and requires prospective validation.

DOI: 10.1016/j.jad.2020.12.119 Medicine